{"id":"4370563dc147","type":"article","url":"https://hartvaat.nl/2022/10/04/2022-acc-expert-consensus-niet-statine-therapieen-voor-ldl-verlaging-bij-ascvd/","title":"2022 ACC Expert Consensus: niet-statine therapieën voor LDL-verlaging bij ASCVD","title_en":"2022 ACC Expert Consensus Decision Pathway on the Role of Nonstatin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Solution Set Oversight Committee.","category":"cholesterol","category_label":"Cholesterol","professions":["apotheker","cardioloog","huisarts","internist"],"tags":["ezetimibe","lipidenverlaging","niet-statine-therapie","pcsk9-remmers"],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2022.07.006","source_url":"https://doi.org/10.1016/j.jacc.2022.07.006","authors":["Donald M Lloyd-Jones","Pamela B Morris","Christie M Ballantyne","Kim K Birtcher","Ashleigh M Covington","Sondra M DePalma","Margo B Minissian","Carl E Orringer","Sidney C Smith","Ashley Arana Waring","John T Wilkins"],"significance":9,"published":"2022-10-04","source_date":"2022-10-04","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lipidenverlaging-stappenplan/","https://hartvaat.nl/kennis/lipiden/lipidenmedicatie-bij-ckd/"],"congress":"","summary_en":"The 2022 ACC Expert Consensus updated the decision pathway for nonstatin lipid-lowering therapies, integrating evidence on bempedoic acid and inclisiran alongside ezetimibe and PCSK9 monoclonal antibodies. The document provided practical algorithms for escalating therapy to achieve LDL-cholesterol targets.","created":"2026-07-03T10:29:59Z","updated":"2026-07-03T13:29:05Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"ACC expert consensus document actualiseerde het beslispad voor niet-statine therapieën bij ASCVD. Ezetimibe, PCSK9-remmers, bempedoïnezuur en inclisiran worden gepositioneerd op basis van LDL-doelen en risicoprofiel. Het document integreert nieuw bewijs over bempedoïnezuur en inclisiran.","abstract_original":""}